Wedbush Upgrades Cidara Therapeutics (CDTX) to Outperform

Wedbush analyst Robert Driscoll upgraded Cidara Therapeutics (NASDAQ: CDTX) from Neutral to Outperform with a price target of $4.00 (from $2.00).

For an analyst ratings summary and ratings history on Cidara Therapeutics click here. For more ratings news on Cidara Therapeutics click here.

Shares of Cidara Therapeutics closed at $2.35 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• KP Tissue Inc. (KPT:CN) (KPTSF) PT Raised to Cdn$13.50 at Desjardins
• Calian Group Ltd (CGY:CN) (CLNFF) PT Raised to Cdn$109 at Desjardins